Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.41 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502935 | 1.00 | LMNA (0.54) | LMNATRPA1CCR5HKDC1AOC3 | |
| SCHEMBL2339413 | 1.00 | LMNA (0.54) | LMNATRPA1CCR5HKDC1AOC3 | |
| SCHEMBL27361066 | 0.98 | LMNA (0.52) | LMNATRPA1CCR5HKDC1AOC3 | |
| Oxalic Acid SCHEMBL6423864 | 0.92 | LMNA (0.47) | LMNATRPA1CCR5GABBR2GABBR1 | |
| SCHEMBL148756 | 0.85 | TRPA1 (0.48) | LMNATRPA1GABBR2GABBR1TAAR1 | |
| SCHEMBL169508 | 0.85 | LMNA (0.56) | LMNATRPA1CCR5HKDC1AOC3 | |
| Hypochlorous Acid SCHEMBL11415854 | 0.83 | LMNA (0.56) | LMNATRPA1CCR5HKDC1AOC3 | |
| Ammonia Solution, Strong SCHEMBL1640901 | 0.82 | LMNA (0.54) | LMNATRPA1CCR5HKDC1AOC3 | |
| SCHEMBL1144766 | 0.82 | AOC3 (0.47) | LMNATRPA1AOC3ESR1ESR2 | |
| SCHEMBL1144424 | 0.82 | TRPA1 (0.50) | LMNATRPA1CCR5HKDC1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421200-B2 | Manganese-catalysed hydrogenation of esters | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2025-09-23 | — | — | US | disclosed |
| CN-120136669-A | Manganese catalyzed ester hydrogenation | 圣安德鲁斯大学董事会 | 2025-06-13 | — | — | CN | disclosed |
| EP-3737663-B1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | UNIV COURT UNIV ST ANDREWS (GB) | 2023-02-22 | — | — | EP | disclosed |
| US-20210053932-A1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2021-02-25 | — | — | US | disclosed |
| EP-3737663-A1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | University Court of The University of St Andrews (GB) | 2020-11-18 | — | — | EP | disclosed |
| CN-111587238-A | Manganese catalyzed ester hydrogenation | 圣安德鲁斯大学董事会 | 2020-08-25 | — | — | CN | disclosed |
| US-9132136-B2 | Pharmaceutical combination | HOFFMANN-LA ROCHE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2114906-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-20130345201-A1 | PHARMACEUTICAL COMBINATION | HOFFMANN-LA ROCHE INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8604061-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| EP-1126836-B1 | BENZAMIDE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2007-02-14 | — | — | EP | disclosed |
| CN-1092639-C | Benzene-fused heterocyclic derivative and use thereof | TORAY INDUSTRIES (JP) | 2002-10-16 | — | — | CN | disclosed |
| EP-1126836-A4 | BENZAMIDE POTASSIUM CHANNEL INHIBITORS | MERCK & CO INC (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6323235-B1 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS AND ENZYME INHIBITORS | OHTAKE ATSUSHI (JP) | 2001-11-27 | — | — | US | disclosed |
| EP-1126836-A1 | BENZAMIDE POTASSIUM CHANNEL INHIBITORS | Merck & Co., Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6194458-B1 | 1-(2-METHOXYPHENYL)-1-OXO-2-AZA-(S)-4-I-BUTYL-4-PHENYLBUTANE, FOR EXAMPLE; TREATING VARIOUS CONDITIONS INCLUDING TRANSPLANTATION REJECTION OF ORGANS OR TISSUES IN A PATIENT; IMMUNOSUPPRESSANT COMPOSITIONS | MERCK & CO., INC. | 2001-02-27 | — | — | US | disclosed |
| WO-2000025774-A1 | BENZAMIDE POTASSIUM CHANNEL INHIBITORS | MERCK & CO., INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| US-6043264-A | A THROMBOXANE A2 RECEPTOR ANTAGONIST FOR TREATING HYPERTENSION, THROMBOSIS, ISCHEMIC HEART DISEASES, CIRCULATORY DISEASES, ARTERIOSCLEROSIS, PLATELET FUNCTION DISORDER, HYPERLIPIDEMIA, NEPHRITIS OR ASTHMA | TORAY INDUSTRIES, INC. (JP) | 2000-03-28 | — | — | US | disclosed |
| CN-1148381-A | Benzene-fused heterocyclic derivative and use thereof | TORAY INDUSTRIES (JP) | 1997-04-23 | — | — | CN | disclosed |
| EP-0751126-A1 | BENZENE-FUSED HETEROCYCLIC DERIVATIVE AND USE OF THE SAME | TORAY INDUSTRIES, INC. (JP) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421200-B2 | Manganese-catalysed hydrogenation of esters | ADH5, HDHD5, ADH1A | LMNA 3128/4885TRPA1 4233/4885CCR5 2948/4885 |
| US-20130345201-A1 | PHARMACEUTICAL COMBINATION | TAAR1, TAAR5, MC2R | LMNA 4479/4885TRPA1 776/4885CCR5 1488/4885 |
| US-20210053932-A1 | MANGANESE-CATALYSED HYDROGENATION OF ESTERS | ADH5, HDHD5, ADH1A | LMNA 3128/4885TRPA1 4233/4885CCR5 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.